CytoSorbents amends royalty agreement with ROKK, redefines gross revenue scope

Cytosorbents Corp

Royalty rate remains 3% of gross revenues from CytoSorb sales under amended agreement.
Amended and Restated Agreement clarifies definitions of 'gross revenue' with specified deductions.
Covered Products now explicitly include CytoSorb, VetResQ, ECOS-300CY, and certain DrugSorb versions.
Agreement dated August 16, 2024, amends the original 2003 Letter Agreement with ROKK.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.